Identity
ARA-290 is an erythropoietin-derived investigational peptide designed to separate tissue-protection signaling from red-cell production.
Selected study only; not a complete clinical review.
Peptide library
ARA-290 (Cibinetide)
Your guide to this compound.
Mechanism illustrationEnlarge
Evidence in perspective
A small, short phase II neuropathy study is encouraging enough to study further. Symptoms, metabolic outcomes and subgroup nerve imaging do not constitute replicated long-term disease modification.
About this assessment
Existing source snapshot critically reassessed.
Based on the selected source scope described in this profile, often an indexed abstract. Full methods and clinician sign-off remain pending; no systematic-review claim.
Editorial assessment · 2026-09-07
Who was studied
Adults with type 2 diabetes and painful neuropathy; phase 2.
What the sources found
The short study reported improvements in neuropathic symptoms and metabolic measures, with a subgroup corneal-nerve finding.
Regulatory scope
Current authorization for the exact product and jurisdiction was not independently checked in this snapshot. A clinical trial is not marketing authorization.
What remains unknown
Selected indexed primary-study abstract reviewed. Full methods, bias, all safety outcomes, product stability, current jurisdictional authorization and a comprehensive literature search remain outstanding. This is not a complete clinical review.
How it works
ARA-290 is an erythropoietin-derived investigational peptide designed to separate tissue-protection signaling from red-cell production.
The study-specific findings below distinguish biological activity from demonstrated treatment benefit.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Reported adverse effects
- No potential safety issue was identified in this short study; uncommon or delayed harms remain unresolved.
Selected study only; not a complete clinical review.
Contraindications
- A complete contraindication and interaction review remains outstanding.
Limited clinical evidence
The catalog describes a limited clinical evidence base. Small or uncontrolled studies may not separate treatment effects from chance, placebo effects or bias.
Sources used for this snapshot
Claim-by-claim evidence
Benefits
The short study reported improvements in neuropathic symptoms and metabolic measures, with a subgroup corneal-nerve finding.
Selected study only; not a complete clinical review.
Adverseeffects
No potential safety issue was identified in this short study; uncommon or delayed harms remain unresolved.
Selected study only; not a complete clinical review.
References
ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. 2015.
PMID: 25387363
Catalog review date: Sep 7, 2026. This date alone does not establish independent clinical review.